Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.51 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc at RBC Global Healthcare Conference Transcript

May 19, 2020 / 01:45PM GMT
Release Date Price: $566.17 (-0.30%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

Hi, this is Kennen MacKay from RBC, and it's my great pleasure to kick off the first of my fireside chats with Regeneron. And from Regeneron, I'm joined by Bob Landry, the Executive Vice President of Finance and the Chief Financial Officer of Regeneron.

Bob, thank you so much for joining us this morning.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Kennen, thanks for the invite. This is kind of inaugural for Regeneron to be with RBC, and we're very, very happy. Again, I wish we could be in person. And I hope everyone out there listening is -- are staying very, very safe in this trying times.

Let me open up with our FLS and then get into some opening comments. So again, I'd like to remind you that remarks made on the webcast, they include forward-looking statements about Regeneron. Such statements may include but are not limited to those related to Regeneron and its products and business, financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot